Factors that could cause our actual results to differ materially from those in this Quarterly Report include the risk factors described in our Annual Report on Form 10-K
−Removed: filed with the SEC on March 24, 2022.
−Removed: For risk factors related to the proposed ProKidney Business Combination, see the “Risk Factors” section of the preliminary proxy statement on Schedule 14A that we have filed with the SEC relating to our proposed ProKidney Business Combination.
−Removed: There have been no material changes in our risk factors since such filings, except for the following:
−Removed: Changes in laws or regulations or how such laws or regulations are interpreted or applied, or a failure to comply with any laws or regulations, may adversely affect our business, including our ability to negotiate (if we do not complete the ProKidney Business Combination) and complete our initial Business Combination, and results of operations.
−Removed: We are subject to laws and regulations enacted by national, regional and local governments.
−Removed: In particular, we are required to comply with certain SEC and other legal requirements, our business combination may be contingent on our ability to comply with certain laws and regulations and any post-business combination company may be subject to additional laws and regulations.
−Removed: Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly.
−Removed: A failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial Business Combination, and results of operations.
−Removed: In addition, those laws and regulations and their interpretation and application may change from time to time, including as a result of changes in economic, political, social and government policies, and those changes could have a material adverse effect on our business, including our ability to negotiate and complete our initial Business Combination, and results of operations.
−Removed: On March 30, 2022, the SEC issued proposed rules that would, among other items, impose additional disclosure requirements in business combination transactions involving SPACs and private operating companies;
−Removed: amend the financial statement requirements applicable to business combination transactions involving such companies;
−Removed: update and expand guidance regarding the general use of projections in SEC filings, as well as when projections are disclosed in connection with proposed business combination transactions;
−Removed: increase the potential liability of certain participants in proposed business combination transactions;
−Removed: and impact the extent to which SPACs could become subject to regulation under the Investment Company Act of 1940.
−Removed: These rules, if adopted, whether in the form proposed or in revised form, may materially adversely affect our business, including our ability to negotiate (if we do not complete the ProKidney Business Combination) and complete our initial business combination (if we do not complete the ProKidney Business Combination prior to such adoption)
−Removed: and may increase the costs and time related thereto.
−Removed: Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.
+Added: filed with the SEC on March 24, 2022 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 16, 2022.
+Added: For risk factors related to the proposed Business Combination, see the “Risk Factors” section of the definitive proxy statement on Schedule 14A that we have filed with the SEC relating to the Business Combination.
+Added: For the quarter ended June 30, 2022, there were no material changes in our risk factors since such filings.
+Added: Unregistered Sales of Equity Securities and Use of Proceeds
+Added: Defaults Upon Senior Securities
+Added: Mine Safety Disclosures
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.